Currently Viewing:
AMCP 2017
Dr Jennifer Graff on How Payers Make Decisions
August 01, 2017
Laura Topor Discusses Challenges of e-Prescribing Specialty Medications
July 11, 2017
Dr Jacqueline Glover: Financial Knowledge Is Part of Informed Consent
July 10, 2017
Laura Topor Explains the Value of Real-Time Benefit Transactions
June 27, 2017
Dr Jacqueline Glover: Clinicians' Obligations of Justice Regarding Costs of Care
June 24, 2017
Dr Lou Garrison Discusses Challenges of Working With Real-World Data
June 16, 2017
Dr Neil Minkoff Explains How 340B Impacts Pharmacies and Payers Differently
June 15, 2017
Dr Matthew Pickering on Working With Health Plans on Measure Implementation
June 09, 2017
Laura Topor: Clearing Up Misconceptions About e-Prescribing
June 07, 2017
Dr Jacqueline Glover Discusses the Complicated Balance of Ethics in Drug Trials
June 05, 2017
Dr Richard J. Willke Discusses Challenges of Working With Real-World Data
June 02, 2017
Susan A. Cantrell Explains the Necessity of Pre- and Post-Approval Communications
May 31, 2017
Dr Neil Minkoff Discusses Evolution and Consequences of 340B Programs
May 30, 2017
Dr Doug Hillblom Discusses Legislative Pushes Toward e-Prescribing
May 25, 2017
Dr Matthew Pickering Describes Challenges of New Measure Implementation
May 24, 2017
Dr Aimee Tharaldson Discusses the Orphan Drug Approval Trend
May 22, 2017
Dr Gail Bridges on the Importance of Real-World Results Matching Clinical Trial Outcomes
May 21, 2017
Dr Liz Zhou Discusses Real-World Implications of Toujeo Switching Trial
May 19, 2017
Dr Richard J. Willke on the Value of Real-World Data for Health Plans
May 18, 2017
Currently Reading
Dr Lou Garrison on the Discussions Surrounding Outcomes-Based Arrangements
May 17, 2017

Dr Lou Garrison on the Discussions Surrounding Outcomes-Based Arrangements

Although it may be costly to negotiate and implement risk-based arrangements, these agreements are a valuable tool for testing outcomes in the real world among complex patients, explained Lou Garrison, PhD, professor emeritus in the Department of Pharmacy, University of Washington.


Although it may be costly to negotiate and implement risk-based arrangements, these agreements are a valuable tool for testing outcomes in the real world among complex patients, explained Lou Garrison, PhD, professor emeritus in the Department of Pharmacy, University of Washington.

Transcript (slightly modified)

As we move from fee-for-service to value-based models of care and payment, how are risk-based arrangements meeting the needs of the various stakeholders, including the patient?

At this stage, I wouldn’t say we’re meeting those needs. I would say that there’s tremendous interest around the US healthcare system with many manufacturers and payers looking to outcomes-based agreements. Most times, there’s a lot of discussion and it’s only rarely that something is implemented, and that’s because of things like negotiation issues, the costs of negotiation, the costs of setting up the data infrastructure, make it difficult to reach agreement and measure the things that you need to measure.

Now, obviously, in certain circumstances, it’s very difficult to measure long-term outcomes, for example. You have to do long, expensive trials or follow-up, so that makes it a challenge because the decision is often around launch and negotiating the price at launch. I think that’s making it difficult, but it’s clear there’s more interest, and as we improve our data systems, then hopefully we can measure those outcomes.

Again, I look at those agreements as the first step of measuring what happens in the real world, after that trial. We move from a situation where we may have a few hundred patients in a trial, versus up to 10,000 or 30,000 sometimes, but moving into tens of thousands of people in the real world. That’s what we want to see is how things are performing in the real world, in a more complicated mix of patients.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!